Pembrolizumab, a groundbreaking cancer drug, has shown remarkable success in doubling the survival rate for patients. This biologic therapy is particularly effective in individuals with elevated levels of the PD-L1 protein, indicating heightened immune system activity. Even those without high PD-L1 levels have experienced significant benefits, with a notable reduction in the risk of cancer recurrence or metastasis.
Read more from firstpost.com
